Skip to content

Home
About Us
- Board of Directors
- Management Team
Technology
News/Resources
Investor Centre
Contacts

ASX Announcements 2014

10 Dec 2014
Share Registry Change
4 Dec 2014
Presentation to Investors
3 Dec 2014
Biotron Completes Enrolment in Phase 2 Hepatitis C Trial of BIT225
3 Dec 2014
New Issue Announcement
20 Nov 2014
Options
13 Nov 2014
Results of Annual General Meeting
13 Nov 2014
Presentation to Annual General Meeting
12 Nov 2014
Director’s Interests
5 Nov 2014
Fully Underwritten $4.06 Million Rights Issue Closes Oversubscribed
3 Nov 2014
Quarterly Report 30 September 2014
15 Oct 2014
New Issue Announcement
15 Oct 2014
Prospectus
15 Oct 2014
Fully Underwritten Rights Issue
14 Oct 2014
Annual Report and Notice of AGM
13 Oct 2014
Request for Trading Halt
10 Oct 2014
BIT225 Trial Results Show Effective Cure of Hepatitis C
29 Aug 2014
Year End Accounts and Preliminary Final Report
24 Jul 2014
Quarterly Report 30 June 2014
23 Jul 2014
BIT225 Reverses HIV-Induced Impairment of the Immune System
6 Jun 2014
Response to ASX Compliance Letter
27 May 2014
Presentation to Investors May 2014
23 May 2014
BIT225 HCV Trial Update – Thailand
28 Apr 2014
Quarterly Report 31 March 2014
4 Apr 2014
R&D Tax Incentive
31 Mar 2014
April 2014 Edition of BITNews
11 Mar 2014
Update on BIT225 HCV Program
6 Mar 2014
BIT225 HIV/HCV Trial Patients Virus Free at Six Months
21 Feb 2014
Half-year report 31 December 2013
13 Feb 2014
Key USA Patent allowed for Biotron’s BIT225
23 Jan 2014
Response to ASX Compliance Letter
21 Jan 2014
Quarterly Report 31 December 2013
14 Jan 2014
Biotron to Present at Biotech Showcase 2014

<<
2024

2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
>>

Investor Centre

Investor Centre

© Biotron Limited 2016 ABN 60 086 399 144 Site updated 25 September 2024 Legal Notices and Privacy